Positions

Overview

  • Introduction & Clinical Interests:

    I am a clinician and clinical investigator with particular interest in lymphoma, including both B-cell and T-cell lymphomas. My priority is to deliver the best possible care to patients and increase access to clinical trials and state of the art therapies.

    Research:

    In my research pursuits, I hope to help develop novel immune-based therapies for lymphoma that harness the immune system to achieve durable remissions with decreased toxicity.I am interested in immune-based therapies for lymphoma, including transplant, chimeric antigen receptor (CAR) T-cell therapy, and checkpoint blockade. I have a particular interest in immunotherapy and targeted therapy for cutaneous T-cell lymphomas.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Enhanced Efficacy and Increased Long-Term Toxicity of CNS-Directed, AAV-Based Combination Therapy for Krabbe Disease.  Molecular Therapy.  29:691-701. 2021
    2020 A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma.  Biology of Blood and Marrow Transplantation.  26:2223-2228. 2020
    2020 Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.  Current Hematologic Malignancy Reports.  15:9-19. 2020
    2019 Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation status.  Blood Cancer Journal.  9. 2019
    2019 Choosing induction chemotherapy in therapy-related acute myeloid leukemia 2019
    2018 Primary Bone Marrow Diffuse Large B-cell Lymphoma Presenting as Transverse Myelitis.  American Journal of the Medical Sciences.  356:561-566. 2018
    2017 Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia..  Clinical Case Reports.  5:899-901. 2017
    2015 Mechanism-Based Combination Treatment Dramatically Increases Therapeutic Efficacy in Murine Globoid Cell Leukodystrophy 2015
    2015 Prognostic significance of [18F]fluorodeoxyglucose-positron emission tomography in peripheral T-cell lymphoma treated with stem cell transplantation: a retrospective analysis 2015
    2012 Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.  Nature.  482:400-404. 2012
    2010 The ARF Tumor Suppressor Regulates Bone Remodeling and Osteosarcoma Development in Mice.  PLoS ONE.  5:e15755-e15755. 2010
    2009 Chapter 21 Monitoring Autophagy in Lysosomal Storage Disorders.  Methods in Enzymology.  417-449. 2009
    2008 Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease.  Human Molecular Genetics.  17:3897-3908. 2008

    Chapter

    Year Title Altmetric
    2020 Chronic Leukemias.  541-563. 2020

    Research Overview

  • I am interested in immune-based therapies for lymphoma, including transplant, chimeric antigen receptor (CAR) T-cell therapy, and checkpoint blockade.
    I have a particular interest in immunotherapy and targeted therapy for cutaneous T-cell lymphomas.

    • Principal Investigator On

    Investigator On

    Education And Training

  • The University of Alabama at Birmingham Internal Medicine, Residency
  • Washington University in St. Louis School of Medicine Hematology & Oncology, Postdoctoral Fellowship
  • Doctor of Medicine, Washington University/St. Louis 2014
  • Master of Science in Immunology, Washington University/St. Louis 2014
  • Master of Science, 2011
  • Bachelor's Degree, 2007

    • Full Name

  • Lauren Shea